Table 1.
The main characteristics of studies.
| Median age, yr (range) | Sex male/female | Tumor stage | Sample origin | ctDNA (+) | ctDNA (−) | ctDNA (+) recurrence number | ctDNA (−) recurrence number | ctDNA measuring time | Gene mutation detected | Median follow time (mo) | Author, yr | Type of study | Detction platform | Numbers of patients |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 65 (23–87) | 131/99 | II | Plasma | 20 | 210 | 14 | 20 | 4–10 wk | SMAD4, TP53, AKT1, APC, BRAF, CTNNB1, ERBB3, FBXW7, HRAS, KRAS, NRAS, PIK3CA, PPP2R1A, RNF43, POLE | 27 | Tie, 2016 | Prospective cohort | SafeSeq-S | 230 |
| 71 (48–93) | 61/33 | I, II, III | Plasma | 14 | 55 | 8 | 10 | 6–8 wk | ACVR2A, AKT1, AMER1, APC, ARID1A, RAF, CTNNB1, EGFR, ERBB3 (HER3), ERBB4 (HER4), FAT4, FLNA, FBXW7, HRAS, KMT2C, KRAS, MEK1, NRAS, PIK3CA, POLE, PP2R1A, PTEN, RNF43, SMAD2, AD4, SOX9, TCF7L2, TGFBR2, and TP53 | 24.7 | Tarazona, 2019 | Prospective cohort | QIA-Seq | 94 |
| 64 (26–82) | 49/47 | III | Plasma | 20 | 76 | 11 | 13 | 42 d | APC, KRAS, TP53, SMAD4, RNF, BRAF, PIK3CA | 28.9 | Tie, 2019 | Prospective cohort | SafeSeq-S | 96 |
| 69 (43–91) | 73/52 | I, II, III | Plasma | 10 | 84 | 7 | 10 | 30 d | TP53, APC, KRAS, BRAF, PIK3CA, FBXW7, SMAD4, TCF7L2, SDK1, HMCN1, RNF43, DMD, ARID1A, FAT2, ABCA12, ANK2, SO X9, YH11, BMPR2, ATM, SPAG17, TPTE, NTNAP2, RNF17, WBSCR17, ITPR2, WDFY3 | 12.5 | Reinert, 2019 | Multicenter, prospective cohort | Hi-Seq | 125 |
| 64 (54–70) | 576/441 | III | Plasma | 140 | 877 | 44 | 151 | 35–50 d | WIF1 and NPY | 79 | Taieb, 2021 | Multicenter, randomized controlled trial | Methylation ddPCR and NGS | 1017 |
| 6 1(25–86) | 90/61 | III | Plasma | 24 | 127 | 13 | 26 | 30 d | 197 cancer-related genes | 33.5 | Li, 2022 | Prospective, observational cohort study | Targeted sequencing panel | 151 |
ctDNA = circulating tumor DNA, ddPCR = droplet-based digital polymerase chain reaction.